TLSA - Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

Tiziana Life Sciences said the last patient has begun dosing in its Phase 2 intranasal foralumab trial in early/mild Alzheimer’s. Topline data are anticipated in Q1 2027.Material DetailsContext by AI AnalystThis is a mid-stage R&D milestone, shifting the Alzheimer’s program from enrollment risk to…